Document Detail


Amlodipine/Valsartan Single-Pill Combination: A Prospective, Observational Evaluation of the Real-Life Safety and Effectiveness in the Routine Treatment of Hypertension.
MedLine Citation:
PMID:  22271158     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
INTRODUCTION: As several international guidelines on hypertension have now recommended, singlepill/fixed-dose combination antihypertensive therapies may be particularly beneficial as firstline therapy in high-risk patients, in whom more rapid and pronounced blood pressure (BP) control is desired. Upon the single-pill combination of amlodipine and valsartan becoming available, the authors conducted this international, observational study to evaluate its efficacy and safety in a real-life practice setting. METHODS: This prospective, open-label, postmarketing surveillance study enrolled adults with arterial hypertension (systolic BP >140 mmHg and/or diastolic BP >90 mmHg) who were prescribed antihypertensive therapy with single-pill combination amlodipine/valsartan 5/80, 5/160, or 10/160 mg once daily. Patients were observed over a 3-month period (12 weeks) with approximately monthly intervals between clinic visits. RESULTS: A total of 8336 patients completed all study visits and were included in the efficacy analysis. Mean age was 54.7 years and 83.4% of patients had received prior antihypertensive therapy. BP reductions were dose related. Overall, mean BP was reduced from 165.0/99.3 mmHg at baseline to 128.7/80.4 mmHg at 12 weeks (36.3/18.9 mmHg; P<0.0001). The magnitude of BP reduction rose with increasing severity of baseline BP. Control of BP (<140/90 mmHg) was achieved in 77.7% of patients. Efficacy was consistent in subgroups of patients with comorbidities and regardless of whether patients were previously treated with monotherapy or combination therapy. Adverse events were reported in 5.3% of patients. The incidence of edema declined from 10.4% at baseline to 8.5% at study end. CONCLUSION: Single-pill combination amlodipine/valsartan safely and effectively reduced BP across all hypertension grades and allowed the vast majority of patients to achieve BP goals.
Authors:
Yuri Karpov; Neelesh Dongre; Alexey Vigdorchik; Krisada Sastravaha
Related Documents :
22235818 - Refractory hypertension: definition, prevalence, and patient characteristics.
21701398 - Physical fitness and perceived psychological pressure at work: 30-year ischemic heart d...
21805568 - Assessment of macro- and microcirculation in contemporary critical limb ischemia.
14756678 - An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volu...
7061128 - Carotid sinus baroreceptor control of arterial pressure in renovascular hypertensive su...
14974578 - Effects of extracorporeal shock wave therapy and radial pressure wave therapy on elasti...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-20
Journal Detail:
Title:  Advances in therapy     Volume:  -     ISSN:  1865-8652     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-1-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Russian Cardiology Scientific-Industrial Complex, Moscow, Russia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fixed-dose combinations for treatment of type 2 diabetes mellitus.
Next Document:  Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or ...